Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227779 · ClinicalTrials.gov registry record · Phase 2
B-PaLMZ for TB Meningitis
A Phase 2 study, sponsored by University of Minnesota.
- Not yet
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT07227779 is a Phase 2 study that has not yet begun recruiting, run by University of Minnesota. The registered enrollment target is 240 participants.
The verdict
NCT07227779, a Phase 2 study, has not yet begun recruiting, sponsored by University of Minnesota.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.
Interventions
- DRUG BPaLMZ Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2026-07-20 |
| Est. Completion | 2030-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07227779
The ClinicalTrials.gov registry entry for NCT07227779 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BPaLMZ Regimen is the first listed.
NCT07227779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07227779 about?
NCT07227779 is a clinical study titled "B-PaLMZ for TB Meningitis". This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.
What is the current status of trial NCT07227779?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2026-07-20. Estimated completion is 2030-08-31.
What interventions are being tested in trial NCT07227779?
The interventions under investigation include: BPaLMZ Regimen (DRUG).
Who is sponsoring clinical trial NCT07227779?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.